1. Show article details.

    Varian Brings Machine Learning to Proton Treatment Planning with Eclipse v16

    PR Newswire – 8:15 AM ET 03/31/2020

    PALO ALTO, Calif. Highlights Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technologies like machine learning, Varian, today announced the newest release of its treatment planning system, Eclipse™ v16.

  2. Show article details.

    Medical technology firm IBA says stays operational amid outbreak

    Reuters – 10:03 AM ET 03/26/2020

    Belgian medical technology company Ion Beam Applications said on Thursday that its supply chains and operations were for the most part still running amid the coronavirus outbreak. "We're not in business as usual," the group's chief executive officer Olivier Legrain told Reuters.

  3. Show article details.

    Medical technology company IBA reports 2019 profit despite pricing pressure

    Reuters – 1:55 AM ET 03/26/2020

    Belgian medical technology therapy company Ion Beam Applications reported a small annual core profit on Thursday, meeting its guidance after its first six months ended in the red, and said it faced continued pricing pressure as rivals attempted to gain market share.

  4. Show article details.

    Alabama's Only Proton Therapy Center Treats First Patient with Varian ProBeam

    PR Newswire – 8:15 AM ET 03/17/2020

    PALO ALTO, Calif. "We celebrate this first of many patients who will be treated at UAB with this advanced technology," said Will Ferniany, Ph.D., CEO of the UAB Health System. Dr. James Bonner, chairman of the UAB Radiation Oncology Department added, "This is a landmark moment for the patients of Alabama.

  5. Show article details.

    Varian to Equip New Ethos Personalized Adaptive Therapy Center in Phoenix

    PR Newswire – 8:15 AM ET 03/16/2020

    PALO ALTO, Calif. This new center will be equipped with Varian's Ethos therapy.

  6. Show article details.

    BRIEF-Varian Halcyon 2.0 Treatment System Receives China NMPA Approval

    Reuters – 8:11 AM ET 03/16/2020

    Varian Medical Systems Inc (VAR): * VARIAN HALCYON 2.0 TREATMENT SYSTEM RECEIVES CHINA NMPA APPROVAL Source text for Eikon: Further company coverage:

  7. Show article details.

    Varian Halcyon 2.0 Treatment System Receives China NMPA Approval

    PR Newswire – 7:30 AM ET 03/16/2020

    PALO ALTO, Calif. As an advanced cancer treatment system with a human-centered and user-friendly design, Halcyon is engineered to revolutionize clinical workflow, accelerate installation timeframes, expedite commissioning, simplify training, and automate treatment. Halcyon 2.0 features kV CBCT and Iterative CBCT imaging for better soft tissue definition.

  8. Show article details.

    BRIEF-Quebec Selects Varian To Increase Access To Advanced Cancer Care

    Reuters – 8:45 AM ET 03/11/2020

    Varian Medical Systems Inc (VAR): * QUEBEC SELECTS VARIAN TO INCREASE ACCESS TO ADVANCED CANCER CARE. * VARIAN MEDICAL SYSTEMS (VAR) - GACEQ FILED A NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT TO CO FOR AN ORDER OF 12 MEDICAL LINEAR ACCELERATORS. * VARIAN MEDICAL SYSTEMS (VAR) - AWARD MAKES A TOTAL OF 21 VARIAN LINACS PURCHASED OVER LAST FOUR YEARS IN QUEBEC.

  9. Show article details.

    Quebec Selects Varian to Increase Access to Advanced Cancer Care

    PR Newswire – 8:15 AM ET 03/11/2020

    PALO ALTO, Calif. The GACEQ selection represents new Varian TrueBeam® systems in Rimouski, Chicoutimi, Gatineau, Jewish General Hospital, Trois-Rivieres, and the new Cancer Centre in Abitibi. "We are honored GACEQ selected Varian as its partner to bring these advanced treatments to more patients in Quebec," said Chris Toth, president Varian Oncology Systems.

  10. Show article details.

    Ethos Therapy Continues Global Expansion

    PR Newswire – 8:15 AM ET 03/10/2020

    PALO ALTO, Calif. Adaptive therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment. At Medisch Spectrum Twente Hospital, the first two patients treated were for prostate cancer, at RNSH the first treatment was for head and neck cancer and at Icon Cancer Centre Wahroonga, the first treatment was for prostate cancer.

  11. Show article details.

    BRIEF-Varian Says COVID-19 Outbreak Will Negatively Impact Operating Results

    Reuters – 6:05 AM ET 03/09/2020

    Varian Medical Systems Inc (VAR): * VARIAN PROVIDES AN UPDATE ON EXPECTED IMPACT FROM COVID-19. * SEES Q2 2020 REVENUE $800 MILLION TO $825 MILLION. * COVID-19 OUTBREAK WILL NEGATIVELY IMPACT COMPANY'S OPERATING RESULTS.

  12. Show article details.

    Varian Provides an Update on Expected Impact From COVID-19

    PR Newswire – 6:00 AM ET 03/09/2020

    PALO ALTO, Calif. Across the company's Asia-Pacific geographies, healthcare resources are being prioritized for the treatment and management of the outbreak. While uncertainty remains around the duration, severity and geographic scope of the COVID-19 outbreak, the company preliminarily estimates 7 to 9 percent revenue growth for fiscal year 2020.

  13. Show article details.

    BRIEF-Varian Medical Systems Amended By-Laws To Provide That Any Director May Be Removed

    Reuters – 6:54 AM ET 03/03/2020

    Varian Medical Systems Inc (VAR): * VARIAN MEDICAL SYSTEMS (VAR) - AMENDED BY-LAWS TO PROVIDE THAT ANY DIRECTOR MAY BE REMOVED, BY VOTE OF HOLDERS OF AT LEAST A MAJORITY VOTING POWER Source text: Further company coverage:

  14. Show article details.

    Varian to Attend Upcoming Investor Events

    PR Newswire – 4:30 PM ET 02/27/2020

    PALO ALTO, Calif. Information about the webcast of the company's presentation at the Barclays Global Healthcare Conference will be available through a link on the company website at www.varian.com/investors. About VarianAt Varian, we envision a world without fear of cancer.

  15. Show article details.

    Varian Receives FDA 510(k) Clearance for Ethos Therapy

    PR Newswire – 8:15 AM ET 02/11/2020

    PALO ALTO, Calif. Adaptive therapy provides the ability to alter the patient's treatment based on the patient's anatomy and position at the time of treatment. "Ethos is the long-awaited solution that puts each patient truly at the center of care," said Chris Toth, president Varian Oncology Systems.

  16. Show article details.

    BRIEF-Varian Medical Systems Posts Q1 Non-GAAP EPS Of $1.16

    Reuters – 6:13 PM ET 01/29/2020

    Varian Medical Systems Inc (VAR): * VARIAN REPORTS RESULTS FOR FIRST QUARTER OF FISCAL YEAR 2020. * Q1 NON-GAAP EARNINGS PER SHARE $1.16. * Q1 GAAP EARNINGS PER SHARE $0.96. * Q1 EARNINGS PER SHARE ESTIMATE $1.19 -- REFINITIV IBES DATA. * NO CHANGE TO FISCAL YEAR 2020 GUIDANCE. * QTRLY TOTAL COMPANY REVENUES GREW 12% IN DOLLARS, OR 13% IN CONSTANT CURRENCY, TO $829 MILLION.

  17. Show article details.

    Massachusetts General Hospital Selects Varian Radiotherapy Systems for Cancer Center

    PR Newswire – 4:30 PM ET 01/29/2020

    PALO ALTO, Calif. "We are honored Massachusetts General selected the Varian radiotherapy and radiosurgery systems for its cancer center," said John Kowal, president Varian Oncology Systems for the Americas.

  18. Show article details.

    Varian Reports Results for First Quarter of Fiscal Year 2020

    PR Newswire – 4:09 PM ET 01/29/2020

    PALO ALTO, Calif. First Quarter 2020 Summary  Excludes the year-over-year impact of foreign exchange and growth from our CTSI and Interventional Solutions businesses. Varian today announced its first quarter fiscal year 2020 results.

  19. Show article details.

    Varian Appoints Prof. Dr. Ricky Sharma VP of Clinical Affairs

    PR Newswire – 8:15 AM ET 01/20/2020

    PALO ALTO, Calif. A pioneer in internal radiotherapy and chemotherapy treatments for patients with liver metastases, Dr. Sharma transformed liver cancer care by providing evidence-based data to drive cancer treatment options.

Page:

Today's and Upcoming Events

  • Apr
    22

    VAR to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • Jan
    29

    VAR announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.